Together for medicines that matter
Disclaimer

This presentation (including any information which has been or may be supplied in writing or orally in connection herewith or in connection with any further inquiries) is being delivered on behalf of Evotec SE (the “Company,” “we,” “our” or “us”). This presentation is made pursuant to Section 5(d) and/or Rule 163B of the Securities Act of 1933, as amended, and is intended solely for investors that are qualified institutional buyers or certain institutional accredited investors solely for the purposes of familiarizing such investors with the Company. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy Evotec securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No representations or warranties, express or implied, are made as to the accuracy or completeness of the statements, estimates, projections or assumptions contained in the presentation, and neither the Company nor any of its directors, officers, employees, affiliates, agents, advisors or representatives shall have any liability relating thereto.

Cautionary Note Regarding Forward-Looking Statements

This presentation contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Many of the forward-looking statements contained in this presentation can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and other similar expressions that are predictions of or indicate future events and future trends, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to a variety of factors. The forward-looking statements contained in this presentation speak only as of the date of this presentation, and unless otherwise required by law, we do not undertake any obligation to update them in light of new information or future developments or to release publicly any revisions to these statements in order to reflect later events or circumstances or to reflect the occurrence of unanticipated events.
Welcome

The Management Team

Werner Lanthaler
CEO

Enno Spillner
CFO

Craig Johnstone
COO

Matthias Evers
CBO

Cord Dohrmann
CSO
Agenda

Highlights

Financial performance 9M 2022

Scientific and operational performance 9M 2022

ESG, Outlook and Guidance 2022
Focused on execution and acceleration

9M 2022 – Latest highlights & lowlights

Highlights

- Undisrupted demand in all sectors; New and extended discovery & development agreements and several smaller milestones
- Significant progress in neuroscience collaboration with Bristol Myers Squibb
- Just – Evotec Biologics: Collaboration with Alpine Immune Sciences; U.S. Department of Defense (“DOD”) first contract for monoclonal antibody; Second award after period end; Ground-breaking for biologics facility J.POD® Toulouse, France
- Acquisition of Central Glass Germany, which will operate as Evotec Drug Substance (Germany) GmbH (“Evotec DS”), effective 1 November
- E.MPD molecular database in autoimmune diseases with Hannover Medical School (“MHH”) (after period-end)
- Launch of multi-omics data analysis platform PanHunter (after period-end)

Lowlights

- Delays in milestones and of revenue recognition from scaling biologics manufacturing
- Strong headwinds from rising energy and material costs and overall inflation
Strong profitable growth of base business

Financials 9M 2022 & FY 2022 guidance

Undisrupted demand from all industry sectors

- **Group revenues** of € 510.8 m up 19%
  - Growth of Group revenues, adj. for fx-effects up 13%
  - Growth of base business (excl. milestones, upfront payments, licenses) up 27%

- **Adjusted Group EBITDA**\(^3\) of € 44.6 m down 36%
  - Lower milestones, upfront and license revenues
  - Just – Evotec Biologics in start-up phase
  - Energy / material costs as well as M&A related costs

- **Adjusted Group EBITDA**\(^3\) excluding
  - **Just – Evotec Biologics** of € 84.6 m up 14%
  - Higher utilisation and high margin business compensating lower milestones
  - fx-tailwind of € 12.4 m

Guidance confirmed

- **Very good top-line growth expected**
  - Total Group revenues € 715-735 m; 2021: € 618 m
    (€ 690-710 m at constant exchange rates\(^1\))

- **Accelerated R&D investments for sustained growth**
  - Unpartnered Group R&D expenses of € 70-80 m\(^2\)
    (2021: € 58 m)

- **At least stable adj. Group EBITDA – investing in growth**
  - Adjusted Group EBITDA\(^4\) € 105-120 m (unchanged)
    (2021: € 107.3 m)
    (€ 85-100 m at constant exchange rates\(^1\))

---

\(^1\) EUR/USD 1.18; EUR/GBP 0.86
\(^2\) Evotec focuses its guidance and upcoming reporting on the “unpartnered R&D” part. ID-related R&D expenses will be fully reimbursed by its partner Sanofi (“partnered R&D”)
\(^3\) Before contingent considerations, income from bargain purchase & excl. impairments on goodwill, other intangible & tangible assets as well as the total non-operating result
\(^4\) Excluding M&A related costs (€ -2 m ytd) and before contingent considerations, income from bargain purchase & excl. impairments on goodwill, other intangible & tangible assets as well as the total non-operating result
Agenda

Highlights

Financial performance 9M 2022

Scientific and operational performance 9M 2022

ESG, Outlook and Guidance 2022
## Strong growth & investments in capacity, R&D, SG&A and M&A

Condensed income statement 9M 2022 – Evotec SE and subsidiaries

<table>
<thead>
<tr>
<th>in € m(^1)</th>
<th>9M 2022</th>
<th>9M 2021</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenues</td>
<td>510.8</td>
<td>431.0</td>
<td>19%</td>
</tr>
<tr>
<td>Gross margin</td>
<td>17.9%</td>
<td>23.1%</td>
<td>–</td>
</tr>
<tr>
<td>R&amp;D expenses</td>
<td>(55.3)</td>
<td>(53.5)</td>
<td>3%</td>
</tr>
<tr>
<td>SG&amp;A expenses</td>
<td>(109.9)</td>
<td>(71.0)</td>
<td>55%</td>
</tr>
<tr>
<td>Impairment of intangible assets and goodwill</td>
<td>-</td>
<td>(0.7)</td>
<td>nm</td>
</tr>
<tr>
<td>Other op. income (expenses), net</td>
<td>56.7</td>
<td>51.8</td>
<td>9%</td>
</tr>
<tr>
<td>Operating result</td>
<td>(16.8)</td>
<td>26.1</td>
<td>nm</td>
</tr>
<tr>
<td>Adjusted Group EBITDA(^2)</td>
<td>44.6</td>
<td>70.1</td>
<td>(36)%</td>
</tr>
<tr>
<td>Net income</td>
<td>(148.5)</td>
<td>247.0</td>
<td>nm</td>
</tr>
</tbody>
</table>

- Revenue growth 19% (13%, adjusted for fx-effects); comparison impacted by high milestone contribution in Q3 2021
- Increasing share of unpartnered R&D (+19%)
- SG&A up 55% due to upscaling at all sites, US-listing, consulting fees (M&A, digitalisation), energy costs, higher depreciation & amortisation
- Decline of adj. EBITDA due to change in revenue mix, and cost structure
- Strong net income impact from share price adjustment of Exscientia equity holding

\(^1\) Differences may occur due to rounding

\(^2\) Before contingent considerations, income from bargain purchase and excl. impairments on goodwill, other intangible and tangible assets as well as the total non-operating result
High quality gross margin, clearly identified challenges

Revenues & Gross margin overview – Evotec SE and subsidiaries

<table>
<thead>
<tr>
<th>Revenues (in € m)</th>
<th>Gross margin (in %)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>9M 2021</strong></td>
<td><strong>9M 2022</strong></td>
</tr>
<tr>
<td>Base revenues</td>
<td>Total Margin</td>
</tr>
<tr>
<td>431.0</td>
<td>23.1</td>
</tr>
<tr>
<td>36.5</td>
<td>21.7</td>
</tr>
<tr>
<td>394.5</td>
<td>26.5</td>
</tr>
<tr>
<td>+19%</td>
<td>27.3</td>
</tr>
</tbody>
</table>

- Group revenues € 482.8 m – excluding Just – Evotec Biologics up 22%
- Base revenues € 502.7 m up 27%
- Group base revenues excluding Just – Evotec Biologics of € 474.7 m up 32%
- Group gross margin of 27.3% excluding Just – Evotec Biologics despite lower milestones
- Gross margin excluding milestones of 26.5% significantly improved versus 21.7% despite significantly higher energy and material costs
- fx-tailwind accounts for 1.6 percentage points margin improvement
Acceleration underlying EBITDA growth

Adj. EBITDA overview – Evotec SE and subsidiaries incl./excl. Just – Evotec Biologics

- Group adj. EBITDA decline by 36% to € 44.6 m strongly impacted by start-up costs for Just – Evotec Biologics
- Group adj. EBITDA of € 84.6 m, excl. Just – Evotec Biologics up 14%

Positive
- High margin business
- Higher utilisation
- fx-tailwind

Challenges
- Lower contribution from milestones, upfront and licenses
- Higher energy costs and inflation
- M&A related costs

1) +66% excluding milestone payments
### Strong underlying performance

Segment information 9M 2022 – Evotec SE and subsidiaries

<table>
<thead>
<tr>
<th></th>
<th>EVT Execute</th>
<th>EVT Innovate</th>
<th>Inter-segment elimination</th>
<th>Evotec Group</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenues</strong></td>
<td>526.7</td>
<td>121.9</td>
<td>(137.9)</td>
<td>510.8</td>
</tr>
<tr>
<td><strong>Gross margin</strong></td>
<td>16.2%</td>
<td>14.2%</td>
<td>–</td>
<td>17.9%</td>
</tr>
<tr>
<td><strong>R&amp;D expenses</strong></td>
<td>(4.2)</td>
<td>(62.2)</td>
<td>11.1</td>
<td>(55.3)</td>
</tr>
<tr>
<td><strong>SG&amp;A expenses</strong></td>
<td>(88.2)</td>
<td>(21.7)</td>
<td>–</td>
<td>(109.9)</td>
</tr>
<tr>
<td><strong>Impairment of intangible assets and goodwill</strong></td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td><strong>Other op. income (expenses), net</strong></td>
<td>25.3</td>
<td>31.4</td>
<td>–</td>
<td>56.7</td>
</tr>
<tr>
<td><strong>Operating result</strong></td>
<td>18.3</td>
<td>(35.1)</td>
<td>–</td>
<td>(16.8)</td>
</tr>
<tr>
<td><strong>Adjusted EBITDA&lt;sup&gt;2&lt;/sup&gt;</strong></td>
<td>75.8</td>
<td>(31.2)</td>
<td>–</td>
<td>44.6</td>
</tr>
</tbody>
</table>

- **EVT Execute**: 23% growth including inter-segment revenues; 18% growth of external revenues driven by strong base business (23% excluding Just – Evotec Biologics)
- **EVT Innovate**: 20% growth in 9M 2022 despite high milestone driven comparable base in Q3 2021; demand for precision medicine platforms remains very strong
- Adjusted Group EBITDA influenced by lower contribution from milestones, upfronts and licenses as well as ramp-up costs of Just - Evotec Biologics, energy and material costs as well as M&A costs as part of higher SG&A costs

---

<sup>1</sup> Differences may occur due to rounding
<sup>2</sup> Before contingent considerations, income from bargain purchase and excl. impairments on goodwill, other intangible and tangible assets as well as the total non-operating result
### Strong growth of base business – expanding at high speed

Condensed income statement Q3 2022 – Evotec SE and subsidiaries

<table>
<thead>
<tr>
<th></th>
<th>Q3 2022</th>
<th>Q3 2021</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenues</strong></td>
<td>173.9</td>
<td>159.7</td>
<td>9%</td>
</tr>
<tr>
<td><strong>Gross margin</strong></td>
<td>16.3%</td>
<td>27.0%</td>
<td>–</td>
</tr>
<tr>
<td><strong>R&amp;D expenses</strong></td>
<td>(18.5)</td>
<td>(18.0)</td>
<td>3%</td>
</tr>
<tr>
<td><strong>SG&amp;A expenses</strong></td>
<td>(42.5)</td>
<td>(24.7)</td>
<td>72%</td>
</tr>
<tr>
<td><strong>Impairment of intangible assets</strong></td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td><strong>Impairment of goodwill</strong></td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td><strong>Other op. income (expenses), net</strong></td>
<td>19.0</td>
<td>17.3</td>
<td>10%</td>
</tr>
<tr>
<td><strong>Operating result</strong></td>
<td>(13.5)</td>
<td>17.7</td>
<td>nm</td>
</tr>
<tr>
<td><strong>Adjusted Group EBITDA(^2)</strong></td>
<td>11.0</td>
<td>33.9</td>
<td>-68%</td>
</tr>
<tr>
<td><strong>Net income</strong></td>
<td>(47.3)</td>
<td>134.3</td>
<td>nm</td>
</tr>
</tbody>
</table>

- Reported growth of 9% due to high comparable basis of milestones, upfronts & licenses in Q3 2021 (Δ € 23 m)
- Base revenues increased by 29% in Q3
- Gross margin contraction due to high comparable base in Q3 2021 and Just – Evotec Biologics ramp-up
- Gross margin excluding Just – Evotec Biologics: 28.8%
- SG&A reflects further scaling, **higher energy costs** and M&A
- Adj. EBITDA excluding Just – Evotec Biologics at previous years level despite lower milestones and higher costs

---

1) Differences may occur due to rounding
2) Before contingent considerations, income from bargain purchase and excl. impairments on goodwill, other intangible and tangible assets as well as the total non-operating result

---

\(^1\) Differences may occur due to rounding
\(^2\) Before contingent considerations, income from bargain purchase and excl. impairments on goodwill, other intangible and tangible assets as well as the total non-operating result
Strong balance sheet supports strategic growth

Balance sheet and liquidity – 31 Dec. 2021 vs. 30 Sep. 2022\(^1\) – Evotec SE and subsidiaries

<table>
<thead>
<tr>
<th>Description</th>
<th>31 Dec. 2021</th>
<th>30 Sep. 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Balance sheet total in € m</td>
<td>2,262.7</td>
<td>2,235.2</td>
</tr>
<tr>
<td>Equity Ratio in %</td>
<td>54.3</td>
<td>61.6</td>
</tr>
<tr>
<td>Net Debt ratio (excl. IFRS 16) x adjusted EBITDA(^2)</td>
<td>(7.7)</td>
<td>(5.5)</td>
</tr>
<tr>
<td>Liquidity position in € m</td>
<td>823.7</td>
<td>858.2</td>
</tr>
</tbody>
</table>

- Small total assets increase
- With upfronds and repayment of debt, net debt leverage ratio further expanded to -7.7 x adjusted EBITDA excl. IFRS 16
- Equity ratio reduction predominantly due to share price development of Exscientia holding
- Strong operating cash in-flow, also due to upfronds, largely balances liquidity outflow for further ramp up, capex, equity and M&A

\(^1\) Differences may occur due to rounding
\(^2\) Versus 31 Dec 2021; incl. IFRS16 (4.0) (30 Sep 2022 vs (3.2) (31 Dec 2021)
Agenda

Highlights

Financial performance 9M 2022

Scientific and operational performance 9M 2022

ESG, Outlook and Guidance 2022
Precise medicines with omics, cell therapy & tech convergence

Overview & focus areas to accelerate leadership and profitable growth

PanOmics  iPSC-based Cell Therapies  Just – Evotec Biologics  End-to-end Shared R&D

Data-driven R&D Autobahn to Cures

From disease understanding to precise medicines

Industry leading iPSC capability at scale for off the shelf solutions

Disruptive technology to offer lowest cost, highest quality biologics

Multi-modality end-to-end shared drug discovery & development
Expanded and new alliances with precision medicine platforms

Latest highlights in 9M 2022

- **PanOmics**
- iPSC-based Cell Therapies
- Just – Evotec Biologics
- End-to-end Shared R&D

**Data-driven R&D Autobahn to Cures**

- **Neurodegeneration**: Two new programmes identified for further development
- **Expansion of E.MPD molecular database** into autoimmune diseases
- **Launch of first commercial version of PanOmics data analysis platform**
Offering Software as a Service (SaaS)

PanHunter

PanHunter
Interactive Omics Analysis

Analyse your deep biological omics data at ease

https://panhunter.com/
Delivering health by expanding & improving cell therapy research

Overview 9M 2022

- QRBeta 1.0 – First generation cell therapy for Insulin-dependent diabetes
- iPSC-based beta cells combined with Cell Pouch™

- Acquisition of Rigenerand Srl, Medolla, Italy, now operating as Evotec (Modena) Srl
- Evotec Cell Accelerator: cGMP manufacturing as basis for off-the-shelf cell therapies
Paradigm shift in biologics starting its market entry strategy

Latest highlights in 9M 2022

Data-driven R&D Autobahn to Cures

- Just – Evotec Biologics is in its build up and initial investment phase
- Discovery and pre-clinical programs build a robust pipeline towards commercial contracts

Ground-breaking for second new biologics facility J. POD® Toulouse
We are expanding across disease areas

Just – Evotec Biologics client programmes

<table>
<thead>
<tr>
<th>Disease area</th>
<th>No. of programmes</th>
<th>Discovery</th>
<th>J.MD™ Optimization</th>
<th>Pre-clinical development</th>
<th>Clinical manufacturing</th>
<th>Commercial Manufacturing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oncology</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Autoimmune</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CNS</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infectious diseases</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other / undisclosed</td>
<td>ND¹)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Good initial basis for growth

- >15 partners / >20 programmes
- 3 programmes added in Q3 and one more DOD award in Q4
- Continued emphasis on optimal value mix of
  - Fee for service, \textit{EVOroyalty}, \textit{EVOequity}
- Better access to affordable medicine for all
  - >50% of programmes addressing targets set to reach UN SDG 3²)

¹) Not Disclosed
²) United Nations SustA.I.nable Development Goal 3: Ensure healthy lives and promote well-being for all at all ages
**Key progress since half year results**

- Closed sales is leading indicator of future revenues
- Closed sales 2022 sales show strong growth – indicates market entry progressing and future potential
- Business Development is ramping up further to maximize partnering opportunities in U.S. and Europe

**Just – Evotec Biologics**

<table>
<thead>
<tr>
<th>Closed Sales, Sales in € m</th>
<th>2021</th>
<th>2022¹</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>31</td>
<td>&gt;90</td>
</tr>
</tbody>
</table>

³ YTD as of end Sept 2022
Continued strong performance of shared R&D platform

Latest highlights in 9M 2022

- Several new and extended integrated drug discovery agreements e.g., Viotika, …
- Continued increased demand for integrated CMC (Chemistry, Manufacturing and Control) capabilities e.g., Zogenix, …
- Successful achievement of four performance-based small milestones within existing partnerships; e.g., IND submission, pre-clinical development candidate nomination, and lead optimisation start
- Strong performance of DMPK / ADME-tox testing, e.g., UCB, …
Clear path to the market for rare diseases & precision medicine

Complementing our Abingdon, UK and Verona, Italy API Capabilities

Combined high-end capabilities
- Chemical and Analytical Development teams with strong track record
- State-of-the-art laboratory equipment
- GMP labs and kilo lab facilities
- 3 GMP pilot plants (18 reactors from 100 to 1,600L, 7 m³)
- Commercial API manufacturing capacity

EU GMP certified facility
- ~60 chemical manufacturing experts
- EU cGMP certified and provides highly flexible drug substance manufacturing space with over 5,000 square metres
- Highly flexible product lifecycle management strategies, particularly in rare diseases

Abingdon
Verona
Halle...
“Evotec Inside”
Steady stream of high-value catalysts

Selected pipeline events within next 12 – 24 months

- Phase III & registration (CHN) JingXin in insomnia (EVT201)
- Approval of COVID Biologic (KOR) with SK Bioscience (SKYCovione)
- Phase II data with Bayer in DNP (BAY2395840)
- Phase II initiation with Bayer in Gynaecology (BAY2395840)
- Phase I data in Chikungunya virus (EVT894)
- Phase I data with BMS in CNS (EVT8683)
- Phase I data with Kazia in Oncology (EVT801)
- Phase Ib / II initiation of Exscientia in Oncology (EXS21546)
- Phase I initiation in Covid-19 / HBV (EVT075)
- Phase I initiation with Bayer in Kidney diseases
- Phase I initiations with Kidney diseases with other partners
- Phase I initiation with BMS in CNS
- Phase I initiation with BMS in Oncology
- Multiple co-owned equity companies (not outlined here) will progress in clinic (e.g. Topas, Forge, Carrick, Fibrocor, …)

Multiple programmes across nephrology, oncology, immunology among other therapeutic areas
**EVOequity continues co-owning strategy**

Operational VC model – diversified portfolio with multiple shots on goal

---

**At Equity Holding (≥20%) or Significant influence**

- Eternegen
- Topas Therapeutics
- facio therapies
- AUTOBAHN LABS
- Breakpoint Therapeutics
- NephThera

**Minority Shareholdings (<20%)**

- Ananke Therapeutics
- Exscientia
- FORGE Therapeutics
- ULTRIUM Therapeutics
- Centauri Therapeutics
- IMIDomics
- Sernova Corp

**BRIDGEs**

- LAB282
- LAB150
- AUTOBAHN LABS
- DANUBE LABS
- ARGOBIO STUDIO
- belLAB2122
- belLAB1407

---

https://actionplan.evotec.com/evoequity
Agenda

Highlights

Financial performance 9M 2022

Scientific and operational performance 9M 2022

ESG, Outlook and Guidance 2022
Keeping the promise
ESG & Sustainability – Measures taken in 9M 2022

- **Environment**
  - Starting final phase of SBTi alignment project: Completion of Scope 3 emission assessment
  - Currently setting targets for scopes 1, 2 and 3, where engaging our suppliers is included
  - Installation of first air source heat pump (Building B95 in Abingdon)

- **Social**
  - Expansion of investments in disease areas under UN SDG3
  - Launch of Aurobac Therapeutics, JV with Boehringer Ingelheim and bioMérieux; Targeting Antimicrobial Resistance (“AMR”) with next generation antimicrobials and diagnostics
  - Diversity Month and Pride Month; Joined Proud Science Alliance; Evotec @ London Pride

- **Governance**
  - Governance roadshow of Chairwoman of Supervisory Board
  - Formation of ESG Committee within the Supervisory Board
  - Scoping and prioritisation of ESG projects in 2023
  - Expansion of ESG Team
  - Implementation of Supplier Code of Conduct
## Guidance confirmed – On track towards reaching AP 2025 goal

### Guidance 2022

<table>
<thead>
<tr>
<th></th>
<th>Guidance 2022</th>
<th>YE 2021</th>
<th>Implied growth at midpoint</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Group revenues (H1 2022)</strong></td>
<td>€ 715 – 735 m</td>
<td>€ 618 m</td>
<td>&gt;15%</td>
</tr>
<tr>
<td>(at constant fx-rates(^1))</td>
<td>(€ 690 – 710 m)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Unpartnered R&amp;D(^2)</strong></td>
<td>€ 70 – 80 m</td>
<td>€ 58 m</td>
<td>~30%</td>
</tr>
<tr>
<td><strong>Adjusted EBITDA(^3)</strong></td>
<td>€ 105 – 120 m</td>
<td>€ 107 m</td>
<td>At least stable</td>
</tr>
<tr>
<td>(at constant fx-rates(^1))</td>
<td>(€ 85 – 100 m)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\(^1\) EUR/USD 1.18; EUR/GBP 0.86

\(^2\) No material fx effects as most R&D efforts are carried out in € area

\(^3\) Excl. estimated M&A related costs (€-5 m) & before contingent considerations, income from bargain purchase & excl. impairments on goodwill, other intangible & tangible assets as well as the total non-operating result
Strong finish to the year needed and anticipated

EBITDA bridge 9M 2022 – FY 2022 guidance target

in € m

- Visible contribution from milestones, upfronts & licenses
- Excellent base business with strong operating leverage
- Acceleration of Just – Evotec Biologics revenues leading to very strong operating leverage
- Minor tailwind from fx-rates
- M&A costs not part of initial guidance

1) Excluding M&A costs composing of transaction costs and earnings impact related to acquisitions of Rigenerand (“Evotec Modena Srl”) and Central Glass, Halle (“Evotec DS”)
2) fx-effect/M&A costs
Our mid-term aspirations are “… just the beginning”

2020-2025e Key Performance Indicator goals

<table>
<thead>
<tr>
<th>Category</th>
<th>Goal</th>
<th>Achieved</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adjusted EBITDA(^1)</td>
<td>≥300</td>
<td>106.6</td>
<td>≥180%</td>
</tr>
<tr>
<td>Unpartnered R&amp;D in € m</td>
<td>&gt;100</td>
<td>46.4</td>
<td>&gt;100%</td>
</tr>
<tr>
<td>Co-owned projects(^2)</td>
<td>&gt;250</td>
<td>118</td>
<td>&gt;100%</td>
</tr>
<tr>
<td>Revenues in € m</td>
<td>&gt;1,000</td>
<td>500.9</td>
<td>&gt;100%</td>
</tr>
</tbody>
</table>

\(^1\) Before significant royalties
\(^2\) Incl. Equity participations
| R&D efficiency platforms                                      | • Continued >15% growth of base business (EVOiR&D)  
|                                                            | • Significant capacity and value chain expansion for all modalities and sites |
| Precision medicine platforms                                | • New partnerships, important milestones  
|                                                            | • Multiple clinical trial initiations and progression of co-owned pipeline; (EVOroyalty)  
|                                                            | • Spin-Offs and investments along AP 2025 (EVOequity) |
| Just – Evotec Biologics                                     | • Multiple new partnerships (EVOaccess)  
|                                                            | • Completion of construction for J.POD® Toulouse, France (EU) |
## Upcoming important dates

### Financial calendar 2023

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preliminary FY 2022 results</td>
<td>28 March 2023</td>
</tr>
<tr>
<td>Full year 2022 report</td>
<td>25 April 2023</td>
</tr>
<tr>
<td>Quarterly Statement Q1 2023</td>
<td>10 May 2023</td>
</tr>
<tr>
<td>Virtual Annual General Meeting 2023</td>
<td>20 June 2023</td>
</tr>
<tr>
<td>Half-year 2023 Interim Report</td>
<td>09 August 2023</td>
</tr>
<tr>
<td>Quarterly Statement 9M 2023</td>
<td>08 November 2023</td>
</tr>
</tbody>
</table>
QUESTIONS AND ANSWERS
Your contact:

Volker Braun
*Head of Global Investor Relations & ESG*

+49.(0).40.560 81-775
+49.(0).40.560 81-333 Fax
volker.braun@evotec.com